NO126475B - - Google Patents
Download PDFInfo
- Publication number
- NO126475B NO126475B NO1470/68A NO147068A NO126475B NO 126475 B NO126475 B NO 126475B NO 1470/68 A NO1470/68 A NO 1470/68A NO 147068 A NO147068 A NO 147068A NO 126475 B NO126475 B NO 126475B
- Authority
- NO
- Norway
- Prior art keywords
- meprobamate
- suppositories
- polyethylene glycol
- coconut fat
- active ingredient
- Prior art date
Links
- 239000000829 suppository Substances 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 7
- 244000060011 Cocos nucifera Species 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 11
- 229960004815 meprobamate Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 5
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 3
- 229940054025 carbamate anxiolytics Drugs 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000001593 sorbitan monooleate Substances 0.000 description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 description 3
- 229940035049 sorbitan monooleate Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical class CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- DEFPUWYBNBPCIW-UHFFFAOYSA-N (3-carbamoyloxy-2-methylhexan-3-yl) carbamate Chemical compound C(N)(=O)OC(C(C)C)(OC(N)=O)CCC DEFPUWYBNBPCIW-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- QPLJYAKLSCXZSF-UHFFFAOYSA-N 2,2,2-trichloroethyl carbamate Chemical compound NC(=O)OCC(Cl)(Cl)Cl QPLJYAKLSCXZSF-UHFFFAOYSA-N 0.000 description 1
- AUQKXXDHDKEBEY-UHFFFAOYSA-N 2-methylbutan-2-yl carbamate Chemical compound CCC(C)(C)OC(N)=O AUQKXXDHDKEBEY-UHFFFAOYSA-N 0.000 description 1
- FYZOTOFEIRYYKC-UHFFFAOYSA-N CC(Cl)(CCl)OC(N)=O Chemical compound CC(Cl)(CCl)OC(N)=O FYZOTOFEIRYYKC-UHFFFAOYSA-N 0.000 description 1
- -1 O-toloxypropanediol monocarbamate Chemical compound 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- GXRZIMHKGDIBEW-UHFFFAOYSA-N ethinamate Chemical compound NC(=O)OC1(C#C)CCCCC1 GXRZIMHKGDIBEW-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- HZMVPSHLMIQQNX-UHFFFAOYSA-N pentan-2-yl carbamate Chemical compound CCCC(C)OC(N)=O HZMVPSHLMIQQNX-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B67—OPENING, CLOSING OR CLEANING BOTTLES, JARS OR SIMILAR CONTAINERS; LIQUID HANDLING
- B67B—APPLYING CLOSURE MEMBERS TO BOTTLES JARS, OR SIMILAR CONTAINERS; OPENING CLOSED CONTAINERS
- B67B3/00—Closing bottles, jars or similar containers by applying caps
- B67B3/02—Closing bottles, jars or similar containers by applying caps by applying flanged caps, e.g. crown caps, and securing by deformation of flanges
- B67B3/10—Capping heads for securing caps
- B67B3/12—Capping heads for securing caps characterised by being movable axially relative to cap to deform flanges thereof, e.g. to press projecting flange rims inwardly
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B67—OPENING, CLOSING OR CLEANING BOTTLES, JARS OR SIMILAR CONTAINERS; LIQUID HANDLING
- B67B—APPLYING CLOSURE MEMBERS TO BOTTLES JARS, OR SIMILAR CONTAINERS; OPENING CLOSED CONTAINERS
- B67B3/00—Closing bottles, jars or similar containers by applying caps
- B67B3/02—Closing bottles, jars or similar containers by applying caps by applying flanged caps, e.g. crown caps, and securing by deformation of flanges
- B67B3/10—Capping heads for securing caps
- B67B3/14—Capping heads for securing caps characterised by having movable elements, e.g. hinged fingers, for applying radial pressure to the flange of the cap
Description
Fremgangsmåte for fremstilling av suppositorier inneholdende tungtoppløselig estere. Process for the production of suppositories containing sparingly soluble esters.
Foreliggende oppfinnelse angår en The present invention relates to a
fremgangsmåte for fremstilling av terapeutisk virksomme suppositorier, inneholdende tungt oppløselige estere, fortrinsvis i form av karbamater. method for the production of therapeutically effective suppositories, containing poorly soluble esters, preferably in the form of carbamates.
Forestring av som legemiddel anvendte Esterification of as medicine used
alkoholer medfører ofte en forlenget terapeutisk effekt uten forminskning av akti-viteten. Bruk av karbamater har således vist seg å gi legemidler med høy aktivitet, lang varighet og god toleranse. Estrene, særlig karbamatene, resorberes hurtig og fullstendig etter oral tilførsel, tross at de ofte er tungt oppløselige i vann. Hvis slike estere isteden tilføres i form av suppositorier, fremstilt ifølge konvensjonelle frem-gangsmåter, blir resorbsjonen pr. tidsenhet altfor lav til at opptimal terapeutisk effekt kan oppnåes. alcohols often result in a prolonged therapeutic effect without a reduction in activity. The use of carbamates has thus been shown to provide drugs with high activity, long duration and good tolerance. The esters, especially the carbamates, are quickly and completely absorbed after oral administration, despite the fact that they are often poorly soluble in water. If such esters are instead supplied in the form of suppositories, prepared according to conventional methods, the resorption per unit of time far too low for an optimal therapeutic effect to be achieved.
Ved foreliggende oppfinnelse har det In the present invention, it has
imidlertid vist seg mulig å oppnå en like hurtig og fullstendig resorbsjon når om-handlede legemiddel gis i form av suppositorier, som når det gis per os. Som eksempel på estere etter oppfinnelsen skal nevnes etinylcykloheksanolkarbamat, di-metyletylkarbinolkarbamat, metylpropyl-karbinolkarbamat, diklorisopropanol-karbamat, trikloretanolkarbamat, however, it has proved possible to achieve an equally rapid and complete resorption when the medicinal product in question is given in the form of suppositories, as when it is given per os. As examples of esters according to the invention, ethynyl cyclohexanol carbamate, dimethylethyl carbinol carbamate, methylpropyl carbinol carbamate, dichloroisopropanol carbamate, trichloroethanol carbamate,
O-toloksypropandiolmonokarbamat, O-toloxypropanediol monocarbamate,
metylpropylpropandioldikarbamat methylpropylpropanediol dicarbamate
(meprobamat). (meprobamate).
Den teknikk som er utarbeidet for be-dømmelsen av resorberbarheten av den The technique developed for the assessment of its resorbability
terapeutisk virksomme bestandddelen av suppositorier, krever at forsøksdyr ved kon-trollforsøk pr. os får den ester man ønsker å prøve. Etter at virkningen av en viss mengde preparat gitt pr. os er blitt klar-lagt, gis samme mengde innarbeidet i et suppositorium, og effekten avleses. Det har vist seg hensiktsmessig å anvende meprobamat på grunn av dets muskelslappende virkning på skjelettmuskulaturen. Tilført med magesonde i en mende av 200 mg/kg medfører meprobamat innen en time en på-tagelig avslapping av extremitetmuskula-turen. Når meprobamat tilføres i samme mengde i form av vandige suppositorier, hvor basis består av f. eks. kakaofett, poly-etylenglykolblandinger eller hydrert kokusfett, fåes ingen resorbsjon med slikt resul-tat som oppnåes ved tilførsel per os. therapeutically active component of suppositories, requires that experimental animals in control experiments per os get the ester you want to try. After the effect of a certain amount of preparation given per os has been prepared, the same quantity incorporated in a suppository is given, and the effect is read. It has proven appropriate to use meprobamate due to its muscle relaxing effect on skeletal muscle. Administered by gastric tube in a dose of 200 mg/kg, meprobamate causes a noticeable relaxation of the extremity musculature within an hour. When meprobamate is administered in the same amount in the form of aqueous suppositories, where the base consists of e.g. cocoa fat, polyethylene glycol mixtures or hydrogenated coconut fat, no resorption is obtained with such a result as is achieved with administration per os.
Når samme mengde meprobamat til-føres i form av suppositorier hvor den virksomme bestanddelen er oppløst i en poly-etylenglykolblanding med et dråpepunkt under 40° C, som derpå er emulgert i hydrert kokusfett, hovedsaklig bestående av glyserollaurater, ved hjelp av ikke-jonogene emulgatorer, som sorbitanmonooleat og polyoksyetylensorbitanmonooleat, fåes samme muskelslappende effekt som ved tilførsel per os. When the same amount of meprobamate is added in the form of suppositories where the active ingredient is dissolved in a polyethylene glycol mixture with a drop point below 40°C, which is then emulsified in hydrated coconut fat, mainly consisting of glycerol laurates, using non-ionic emulsifiers , such as sorbitan monooleate and polyoxyethylene sorbitan monooleate, the same muscle-relaxing effect is obtained as with oral administration.
Oppfinnelsen belyses av følgende eksempel, i hvilket den angitte ester kan byt-tes med andre estre om ønskes. The invention is illustrated by the following example, in which the specified ester can be replaced with other esters if desired.
Eksempel I. Example I.
En suppositoriemasse tilberedes av føl-gende stoffer: 15 g meprobamat, 6,8 g polyetylenglykol med en gjennomsnittlig molekylvekt på 600, 12,7 g polyetylenglykol med en gjennomsnittlig molekylvekt på 1000, 0,85 g sorbitanmonooleat, 0,85 g polyoksyetylensorbitanmonooleat, 63,8 g hydrert kokusfett, hovedsaklig bestående av glyse-roltrilaurat og glyserolmonolaurat ved at meprobamatet oppløses i en blanding av de smeltede polyetylenglykolene som har et dråpepunkt under 40° C, hvoretter denne oppløsning blandes med det hydrerte kokusfett, etter at dette er smeltet og blandet med sorbitanmonooleatet og polyoksyetyl-ensorbitanmonooleatet. Den resulterende emulsjon støpes i former, slik at suppositorier med en vekt på 2,7 g og inneholdende 0,4 g meprobamat oppnåes. A suppository mass is prepared from the following substances: 15 g meprobamate, 6.8 g polyethylene glycol with an average molecular weight of 600, 12.7 g polyethylene glycol with an average molecular weight of 1000, 0.85 g sorbitan monooleate, 0.85 g polyoxyethylene sorbitan monooleate, 63 .8 g of hydrogenated coconut fat, mainly consisting of glycerol trilaurate and glycerol monolaurate by dissolving the meprobamate in a mixture of the melted polyethylene glycols that have a drop point below 40° C, after which this solution is mixed with the hydrogenated coconut fat, after this has been melted and mixed with the sorbitan monooleate and the polyoxyethyl ensorbitan monooleate. The resulting emulsion is cast into molds, so that suppositories with a weight of 2.7 g and containing 0.4 g of meprobamate are obtained.
Eksempel 2. Example 2.
En suppositoriemasse tilberedes av føl-gende stoffer: 15 g meprobamat, 10 g polyetylenglykol med en gjennomsnittlig molekylvekt på 600, 17 g polyetylenglykol med A suppository mass is prepared from the following substances: 15 g of meprobamate, 10 g of polyethylene glycol with an average molecular weight of 600, 17 g of polyethylene glycol with
en gjennomsnittlig molekylvekt på 1000, 1 g polyoksyetylensorbitanmonooleat, 57 g an average molecular weight of 1000, 1 g of polyoxyethylene sorbitan monooleate, 57 g
hydrert kokusfett ved at meprobamatet oppløses i de smeltede polyetylenglykoler som også har et dråpepunkt under 40° C, hvoretter oppløsningen emulgeres med den smeltede blanding av kokusfett og emulgatorer. Av den resulterende emulsjon be-redes suppositorier å 2,7 g og inneholdende 0,4 g meprobamat. hydrogenated coconut fat by dissolving the meprobamate in the melted polyethylene glycols which also have a drop point below 40° C, after which the solution is emulsified with the melted mixture of coconut fat and emulsifiers. Suppositories of 2.7 g and containing 0.4 g of meprobamate are prepared from the resulting emulsion.
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67675567A | 1967-10-20 | 1967-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO126475B true NO126475B (en) | 1973-02-12 |
Family
ID=24715847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO1470/68A NO126475B (en) | 1967-10-20 | 1968-04-18 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US3524294A (en) |
| JP (1) | JPS528750B1 (en) |
| AT (1) | AT288899B (en) |
| BE (1) | BE710691A (en) |
| CA (1) | CA925058A (en) |
| CH (1) | CH484829A (en) |
| DE (1) | DE1657167C3 (en) |
| DK (1) | DK138734B (en) |
| ES (1) | ES349161A1 (en) |
| FI (1) | FI50614C (en) |
| FR (1) | FR1550831A (en) |
| GB (1) | GB1178821A (en) |
| IE (1) | IE32052B1 (en) |
| MY (1) | MY7100034A (en) |
| NL (1) | NL154172B (en) |
| NO (1) | NO126475B (en) |
| SE (1) | SE342209B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3660963A (en) * | 1970-05-28 | 1972-05-09 | Crown Cork & Seal Co | Container closing apparatus and method |
| US3807133A (en) * | 1970-12-31 | 1974-04-30 | A Simonazzi | Machine adapted for the application of seals or lids to bottles and containers |
| US3760561A (en) * | 1971-03-01 | 1973-09-25 | Aluminum Co Of America | Capping machine and method |
| US4173104A (en) * | 1978-04-17 | 1979-11-06 | American Flange & Manufacturing Co., Inc. | Bottle capping apparatus and method |
| US4295320A (en) * | 1980-01-09 | 1981-10-20 | Owens-Illinois, Inc. | Closure conversion apparatus for existing closure applicating machines |
| BR9104593A (en) * | 1991-10-18 | 1992-05-12 | J B O Comercial Ltda Me | DEVICE FOR APPLICATION OF LID WITH LACRE IN BOTTLE NOZZLE PROVIDED WITH INTERFERENCE LEADING TO THE SAID LACRE |
| JP3687857B2 (en) * | 1992-05-29 | 2005-08-24 | 澁谷工業株式会社 | Work head changer for rotary container processing equipment |
| GB2268165A (en) * | 1992-06-30 | 1994-01-05 | United Distillers Plc | Adapting capping apparatus for applying different closures |
| IT1289514B1 (en) * | 1996-12-23 | 1998-10-15 | Ronchi Mario Off Mec | QUICK COUPLING DEVICE FOR APPLICATION GROUPS OF CAPS TO CONTAINERS, ESPECIALLY FOR AUTOMATIC MACHINE SPINDLES |
| DE19924659A1 (en) * | 1999-05-28 | 2000-11-30 | Khs Masch & Anlagenbau Ag | Closing station for bottle closing machine has holding down member with holding down spring as independent unit which can be removed from closing element independently |
| EP1182165B2 (en) † | 2000-08-08 | 2012-11-28 | Sidel S.p.A. | Capping head with linear motor actuator |
| US6843360B2 (en) | 2002-03-27 | 2005-01-18 | Douglas Machine, Inc. | Retractable transfer device metering apparatus and methods |
| WO2010127700A1 (en) * | 2009-05-07 | 2010-11-11 | Sidel S.P.A. | Capping head and apparatus for the capping of bottles |
| CN102153034B (en) * | 2011-01-27 | 2012-10-03 | 上海新旭发机械科技有限公司 | High-speed capping machine |
| CN109606770B (en) * | 2018-12-04 | 2022-07-08 | 北京航天斯达科技有限公司 | Three-petal type automatic grasping cap screwing head |
| DE102019103095A1 (en) * | 2019-02-07 | 2020-08-13 | Krones Ag | Device for treating a container |
| CN114725752B (en) * | 2022-04-22 | 2023-11-21 | 深圳市展荣鑫精密技术有限公司 | crown spring machine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3332211A (en) * | 1964-12-24 | 1967-07-25 | American Flange & Mfg | Cap applying apparatus |
| US3308604A (en) * | 1965-03-10 | 1967-03-14 | Crown Cork & Seal Co | Crowning head |
-
1967
- 1967-10-20 US US676755A patent/US3524294A/en not_active Expired - Lifetime
-
1968
- 1968-01-03 IE IE10/68A patent/IE32052B1/en unknown
- 1968-01-11 FR FR1550831D patent/FR1550831A/fr not_active Expired
- 1968-01-11 ES ES349161A patent/ES349161A1/en not_active Expired
- 1968-01-12 FI FI680073A patent/FI50614C/en active
- 1968-01-16 SE SE570/68A patent/SE342209B/xx unknown
- 1968-01-16 GB GB2364/68A patent/GB1178821A/en not_active Expired
- 1968-01-19 NL NL686800856A patent/NL154172B/en not_active IP Right Cessation
- 1968-01-23 AT AT67368A patent/AT288899B/en not_active IP Right Cessation
- 1968-01-26 CA CA010868A patent/CA925058A/en not_active Expired
- 1968-02-06 JP JP43007389A patent/JPS528750B1/ja active Pending
- 1968-02-07 CH CH177468A patent/CH484829A/en not_active IP Right Cessation
- 1968-02-12 DK DK53768AA patent/DK138734B/en not_active IP Right Cessation
- 1968-02-13 BE BE710691D patent/BE710691A/xx not_active IP Right Cessation
- 1968-02-16 DE DE1657167A patent/DE1657167C3/en not_active Expired
- 1968-04-18 NO NO1470/68A patent/NO126475B/no unknown
-
1971
- 1971-12-31 MY MY197134A patent/MY7100034A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK138734B (en) | 1978-10-23 |
| BE710691A (en) | 1968-06-17 |
| GB1178821A (en) | 1970-01-21 |
| NL6800856A (en) | 1969-04-22 |
| DK138734C (en) | 1979-03-26 |
| DE1657167C3 (en) | 1974-11-14 |
| CH484829A (en) | 1970-01-31 |
| FI50614B (en) | 1976-02-02 |
| DE1657167B2 (en) | 1973-05-24 |
| DE1657167A1 (en) | 1971-10-28 |
| US3524294A (en) | 1970-08-18 |
| NL154172B (en) | 1977-08-15 |
| FR1550831A (en) | 1968-12-20 |
| IE32052L (en) | 1969-04-20 |
| AT288899B (en) | 1971-03-25 |
| IE32052B1 (en) | 1973-04-04 |
| ES349161A1 (en) | 1969-04-01 |
| JPS528750B1 (en) | 1977-03-11 |
| CA925058A (en) | 1973-04-24 |
| MY7100034A (en) | 1971-12-31 |
| SE342209B (en) | 1972-01-31 |
| FI50614C (en) | 1976-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO126475B (en) | ||
| Olds | Physiological mechanisms of reward. | |
| EP0014514B1 (en) | Process for the preparation of tablets | |
| NL181006B (en) | METHOD FOR THE PREPARATION OR MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF EPILEPSIA, Dizziness, HYPOKINESIS, SKULL TRAUMA AND GERIATRIC DISEASES, AND METHOD FOR THE PREPARATION OF A 4-AMINIVATIC ACID. | |
| AR035589A1 (en) | ESTERES OF DIFENILMETILCARBOXILICO ACID WITH ANTICOLINERGIC EFFECT, A PROCEDURE FOR ITS PREPARATION, THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT AND THE PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM | |
| ES2043025T3 (en) | A PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION CONTAINING 3- (AMINOPROPIL) METHYL-PHOSPHINIC AS A THERAPEUTIC AGENT. | |
| DE1099128B (en) | Preparations for the care and promotion of the growth of the skin, hair and nails | |
| SE7608092L (en) | NEW STEROIDS | |
| DE1088192B (en) | Process for the production of pelletable or directly usable pharmaceutical granules with adjustable release properties | |
| IE38302L (en) | Aromatic hydroxy amines | |
| ES2157201T3 (en) | CARBAMATE DERIVATIVES OF 4-AMINO-3-ISOXAZOLIDINONES AND 3-AMINO-1-HYDROXIPIRROLIDIN-2-ONAS, A PROCEDURE FOR ITS PREPARATION AND ITS USE AS MEDICATIONS. | |
| ES8400742A1 (en) | Tricyclic ethers, processes for their preparation and their use as medicaments. | |
| Vogel et al. | Habituation and conditioned food aversion | |
| ES453632A1 (en) | Alpha-Amino ketone derivatives | |
| ES2078251T3 (en) | SYSTEM FOR THE REGULATED DISTRIBUTION OF ACTIVE AGENTS AND PROCESS FOR THEIR PREPARATION. | |
| RU2005129278A (en) | PREPARATORY GLUCOCORTICOIDS FOR THE TREATMENT OF PATHOLOGICAL EYE ANGIOGENESIS | |
| Boyd | The antemetic action of chlorpromazine hydrochloride | |
| Nozik et al. | Studies on experimental ocular toxoplasmosis in the rabbit: II. Attempts to stimulate recurrences by local trauma, epinephrine, and corticosteroids | |
| Le Fur et al. | Effects of 4-(3-indolyl-alkyl) piperidine derivatives on brain 5-hydroxytryptamine turnover and on cardiac and brain noradrenaline or 5-hydroxytryptamine depletion induced by 6-hydroxydopamine, H 7512 and 4-chloroamphetamine | |
| US3198704A (en) | Ethyl linoleate emulsions for parenteral injection | |
| Uyeno | Lysergic acid diethylamide and a novel stimulus | |
| DE1467745A1 (en) | Process for the preparation of an agent against pathological meteorism | |
| US3231383A (en) | Process for the stabilization of 1-ascorbic acid in caramel excipients | |
| Caruthers | Nonmotoric influences of meprobamate on established shuttle shock-avoidance performance | |
| SU142111A1 (en) | Means for fighting nematodes and phylloxera |